GlassScriptPhysician profile
Greg J Gerstner
NPI 1629288659
$2,323.46
in general payments reported to CMS, 2019-2025
43 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $214 · 2021: $136 · 2022: $747 · 2023: $161 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.90 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $254.53 | 2019-2022 | |
| Seagen INC. | $210.14 | 2019-2023 | Tivdak, Padcev |
| Novartis Pharmaceuticals Corporation | $185.27 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $139.26 | 2019-2023 | Lynparza, Keytruda |
| Eisai INC. | $103.32 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $99.88 | 2019-2022 | |
| Genzyme Corporation | $96.84 | 2019-2022 | |
| Genentech USA, INC. | $76.63 | 2019-2022 | |
| Pfizer INC. | $76.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.54 | 2019-2020 | |
| Astellas Pharma US INC | $64.43 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $62.55 | 2019-2022 | |
| Janssen Biotech, INC. | $59.84 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $58.00 | 2019-2022 | |
| Amgen INC. | $56.06 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.88 | 2019-2022 | |
| Abbvie INC. | $52.99 | 2022-2023 | |
| Daiichi Sankyo INC. | $51.11 | 2019-2022 | |
| Tosoh Bioscience, INC. | $48.00 | 2019 | |
| Celgene Corporation | $46.90 | 2019-2022 | |
| Taiho Oncology, INC. | $46.55 | 2019-2022 | |
| Secura Bio, INC. | $35.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.70 | 2023 | Libtayo |
| Clovis Oncology, INC. | $32.20 | 2020 | |
| Eusa Pharma (US) LLC | $32.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.95 | 2019 | |
| Deciphera Pharmaceuticals INC. | $30.32 | 2022 | |
| Gilead Sciences, INC. | $26.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $20.86 | 2022 | |
| Advanced Accelerator Applications | $19.67 | 2019 | |
| Cti Biopharma Corp. | $15.93 | 2022 | |
| Emd Serono, INC. | $15.76 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.88 | 2019 | |
| Exelixis INC. | $14.02 | 2019 | |
| G1 Therapeutics, INC. | $12.18 | 2022 | |
| Incyte Corporation | $11.08 | 2019 | |
| Verastem, INC. | $10.90 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Gerstner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.